Ritu Baral

In a report published Thursday, Canaccord Genuity analyst Ritu Baral initiated coverage on Mast Therapeutics (NYSE: MSTX) with a Buy rating and $3.00 price target. In the report, Canaccord Genuity noted, “Initiating coverage with BUY rating, $3.00 target on MST-188 potential in sickle cell disease...

In a report published Monday, Canaccord Genuity analyst Ritu Baral initiated coverage on Regado Biosciences (NASDAQ: RGDO) with a Buy rating and $14.00 price target. In the report, Canaccord Genuity noted, “We see REG1 as a highly innovative new anticoagulant that could improve outcomes across a...

Avanir Pharmeceuticals (NASDAQ: AVNR) stock plummeted yesterday after Gravity Research said Avanir, “engaged in illegal off-label marketing of Nuedexta,” and recommended a strong Sell. Shares closed at $4.79 on Wednesday, a 13 percent decrease. This was the biggest drop of AVNR in three years...

In a report published Tuesday, Canaccord Genuity analyst Ritu Baral downgraded Vical (NASDAQ: VICL) from Buy to Hold, and lowered the price target from $7.00 to $1.40. In the report, Canaccord Genuity noted, “Lowering to HOLD, $1.40 target on Allovectin Ph3 failure and program halt. We still...

In a report published Wednesday, Canaccord Genuity analyst Ritu Baral downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Hold, and lowered the price target from $22.00 to $13.00. In the report, Canaccord Genuity noted, “Lowering to HOLD, $13 target on the expectation of proposed...

In a report published Wednesday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating and $22.00 price target on Cytokinetics (NASDAQ: CYTK). In the report, Canaccord Genuity noted, “Reiterate BUY; $22 target on potential of CK357 in ALS and AMGN-partnered omecamtiv in heart failure. We...